BioSpace News Archive

Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today announced that it will report financial results for the fourth quarter and full year 2020 and provide a corporate update on Wednesday, March 17, 2021, before the U.S. financial markets open

Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for persons undergoing organ or cellular transplantation, as well as those living with immunological diseases, today announced the appointments of Paul Little as Chief Financial Officer, effective today, and Jeff Bornstein, M.D. as Chief Medical Officer, effective April 5, 2021.

Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced the appointment of Garry A. Weems, PharmD, as its Vice President of Clinical Development and Medical Affairs

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced positive data supporting the role of itolizumab as a potential treatment for acute graft-versus-host disease (aGVHD).

Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced the appointment of Eric Dube, Ph.D. to the company’s Board of Directors.

Histogen Inc. (NASDAQ: HSTO), today announced that the U.S. Food and Drug Administration (“FDA”) has confirmed that the Company satisfactorily addressed all clinical hold questions and can proceed with initiation of the planned Phase 1/2 clinical trial of HST-003 to evaluate the safety and efficacy of human extracellular matrix (hECM:HST-003)

Maravai LifeSciences (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, has expanded its contract development and manufacturing organization (CDMO) capabilities at TriLink BioTechnologies (“TriLink”) with the launch of its plasmid DNA (pDNA) manufacturing services . TriLink’s new plasmid services empower customers with the ease of an end-to-end messenger RNA (mRNA) solution

STRATA Skin Sciences, Inc. (“STRATA”), a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced the publication of an independent study on the treatment of vitiligo using the Company’s XTRAC excimer laser

Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced today that it will present at the virtual Oppenheimer 31st Annual Healthcare Conference being held March 16-18, 2021.

Extendicare Inc. announced that it has declared a cash dividend of C$0.04 per common share of the Company for the month of March 2021, which is payable on April 15, 2021 to shareholders of record at the close of business on March 31, 2021.